肺抑瘤膏联合化疗改善晚期EGFR野生型NSGLC生存状况的临床研究

发布时间：2018-11-01 17:53

【摘要】：目的:本临床研究通过对160例IIIB、IV期EGFR野生型非小细胞肺癌临床病例的观察统计,探讨肺抑瘤膏对改善患者生存状况的作用。方法:160例符合入组条件的病例分为单纯化疗组(80例)和联合中药组(80例),通过两组患者治疗前后组内、组间资料的收集,对患者中医证候评分、FACT-L生存质量评分、生存时间及吸烟情况等方面进行对比。结果:联合中药组疗程前后组内组间比较中医证候评分下降,FACT-L生存质量评分的5个模块及总分组内评分上升(P0.05);在组间比较中,FACT-L生理、功能、肺癌特异三个模块及总分评分均高于单纯化疗组(P0.01);且联合中药组相较单纯化疗组表现出了其在生存时间方面的优势。另发现非吸烟者较吸烟者在中医证候、FACT-L评分、生存时间方面均有提高(P0.05)。结论:1.相较单纯化疗对中医证候改变不明显的情况,肺抑瘤膏联合化疗可改善肺癌患者中医证候,并且优于单纯化疗疗效。2.相较单纯化疗使患者多个模块生存质量下降,肺抑瘤膏联合化疗可有效提高患者FACT-L评分,提升改善生存质量,并且能降低化疗毒副作用,较单一运用化疗方案优势明显。3.中医证候评分与FACT-L量表在生理、功能、肺癌特异部分及总分上均有较好的相关性。4.肺抑瘤膏联合化疗方案治疗的患者平均生存期、中位生存期均有延长,总生存期远期观察优于单纯化疗治疗。5.减少吸烟对中医证候、FACT-L评分、总生存期远期观察均有改善,提示吸烟是NSCLC恶化的重要因素。
[Abstract]:Objective: in this clinical study, we observed and counted 160 cases of EGFR wild-type non-small cell lung cancer (NSCLC) in IIIB,IV stage, and discussed the effect of FYO on improving the survival status of the patients. Methods: one hundred and sixty patients were divided into two groups: chemotherapy group (n = 80) and combined Chinese medicine group (n = 80). By collecting the data between groups before and after treatment, the TCM syndromes and FACT-L quality of life of the patients were evaluated. The survival time and smoking status were compared. Results: the scores of TCM syndromes were decreased before and after treatment in the combined Chinese medicine group, and the scores of 5 modules and the total score of FACT-L quality of life were increased (P0.05). In the comparison between groups, FACT-L physiology, function, lung cancer specific three modules and total score were higher than that of chemotherapy group (P0.01), and the combination of traditional Chinese medicine group showed its superiority in survival time compared with the simple chemotherapy group. It was also found that non-smokers had higher TCM syndromes, FACT-L scores and survival time than smokers (P0.05). Conclusion: 1. Compared with chemotherapy alone, the change of TCM syndromes is not obvious, the combination of Feiyao tumour ointment and chemotherapy can improve the TCM syndromes of lung cancer patients, and the curative effect of chemotherapy alone is better than that of chemotherapy alone. 2. Compared with chemotherapy alone, the quality of life of multiple modules of patients was decreased. The combination of lung tumor ointment and chemotherapy can effectively improve the FACT-L score, improve the quality of life, and reduce the side effects of chemotherapy. Compared with the single use of chemotherapy, the advantage is obvious. 3. TCM syndromes score and FACT-L scale in physiology, function, lung cancer specific parts and the total score have a good correlation. 4. 4. The average survival time and median survival time of the patients treated with the combination of Feiyiliuanji ointment and chemotherapy regimen were prolonged, and the long-term observation of the total survival period was better than that of chemotherapy alone. 5. The long term observation of reducing smoking on TCM syndromes, FACT-L score and total survival time showed that smoking was an important factor in the deterioration of NSCLC.
【学位授予单位】：山东中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2

【参考文献】